Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2012-04-11 Merger & Acquisition
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a Stock Purchase Agreement where Arrowhead Research Corporation acquired all outstanding shares of Alvos Therapeutics Inc. in exchange for common stock and potential additional issuances based on milestones. This is a clear announcement of a merger/acquisition transaction. The document is not a full annual or quarterly report, nor is it a simple announcement of a report publication. It is not a proxy, voting result, or management change notice. The key event is a merger/acquisition transaction, so the appropriate classification is Merger & Acquisition (MA). The document length is 3370 characters, which is typical for an 8-K filing announcing a transaction. Confidence is high due to explicit description of the acquisition agreement and related terms.
2012-04-11 English
Annual Report 2012
Annual Report Classification · 95% confidence The document is a detailed response letter from Arrowhead Research Corporation to the SEC's Division of Corporation Finance regarding comments on their previously filed Form 10-K annual report. It references the Form 10-K filing date (December 20, 2011) and addresses specific disclosure comments related to intellectual property, license agreements, and patent details. The content is focused on clarifying and expanding disclosures required in the Form 10-K, which is the company's official annual report. The document is lengthy (15,000 characters) and contains substantive discussion about the company's business and financial disclosures, consistent with an annual report filing. Therefore, the document is best classified as an Annual Report (10-K) related filing, specifically a response to SEC comments on the 10-K. Given the nature and length, it is not a mere announcement or certification but a substantive filing related to the 10-K.
2012-03-31 English
Regulatory Filings 2012
Regulatory Filings Classification · 90% confidence The document text appears to be an encoded or binary attachment (likely a PDF or similar file) embedded within the text, as indicated by the 'begin 644 filename1.pdf' and the presence of encoded data. There is no readable text content, no mention of report titles, fiscal periods, regulatory bodies, or any descriptive information. Given the lack of any discernible content or metadata indicating the nature of the document, and the fact that it is a binary attachment, the best classification is Regulatory Filings (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2012-03-16 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 16, 2012, by Arrowhead Research Corporation. It reports on the departure and election of directors and officers, approval of stock issuances, amendments to equity incentive plans, and ratification of auditors. The key section is Item 5.02, which concerns changes in directors or officers, and Item 5.07, which details voting results from the Annual Meeting of Stockholders. The document primarily announces changes in the company's board and management and the results of shareholder votes. It is not a full annual report, audit report, or earnings release, but rather a current report on management and board changes and voting outcomes. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5113 characters) and content confirm it is not merely an announcement of a report but a substantive filing about management changes and voting results. Confidence is high due to clear SEC form type and content.
2012-02-23 English
Regulatory Filings 2012
Regulatory Filings
2012-02-23 English
Regulatory Filings 2012
Regulatory Filings
2012-02-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.